AI-Driven Predictive Biomarker Discovery with Contrastive Learning to Improve Clinical Trial Outcomes - Arango-Argoty, Gustavo; Bikiel, Damian E.; Sun, Gerald J.; Kipkogei, Elly; Smith, Kaitlin M.; Pro, Sebastian Carrasco; Jacob, Etai (medRxiv, 2024)
Modern clinical trials can capture tens of thousands of clinicogenomic measurements per individual. Discovering predictive biomarkers, as opposed to prognostic markers, is challenging when using manual approaches. To address this, we present an automated neural network framework based on contrastive learning—a machine learning approach that involves training a model to distinguish between similar and dissimilar inputs. We have named this framework the Predictive Biomarker Modeling Framework (PBMF). This general-purpose framework explores potential predictive biomarkers in a systematic and unbiased manner, as demonstrated in simulated “ground truth” synthetic scenarios resembling clinical trials, well-established clinical datasets for survival analysis, real-world data, and clinical trials for bladder, kidney, and lung cancer. Applied retrospectively to real clinicogenomic data sets, particularly for the complex task of discovering predictive biomarkers in immunooncology (IO), our algorithm successfully found biomarkers that identify IO-treated individuals who survive longer than those treated with other therapies. In a retrospective analysis, we demonstrated how our framework could have contributed to a phase 3 clinical trial (NCT02008227) by uncovering a predictive biomarker based solely on early study data. Patients identified with this predictive biomarker had a 15% improvement in survival risk, as compared to those of the original trial. This improvement was achieved with a simple, interpretable decision tree generated via PBMF knowledge distillation. Our framework additionally identified potential predictive biomarkers for two other phase 3 clinical trials (NCT01668784, NCT02302807) by utilizing single-arm studies with synthetic control arms and identified predictive biomarkers with at least 10% improvement in survival risk. The PBMF offers a broad, rapid, and robust approach to inform biomarker strategy, providing actionable outcomes for clinical decision-making.Competing Interest StatementG.A.-A., D.E.B., G.J.S., E.K., K.M.S., and E.J. are current or former employees of AstraZeneca with stock ownership, interests, and/or options in the company. S.C.P. is an employee of Tempus with stock ownership, interests, and/or options in the company.Funding StatementThis study was funded by AstraZenecaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All datasets with human data are publicly available at the following URLs: (1) https://www.uniklinik-freiburg.de/imbi/stud-le/multivariable-model-building.html (2) https://www.nature.com/articles/s41591-018-0134-3I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll human data used are available online at the following URLs: (1) https://www.uniklinik-freiburg.de/imbi/stud-le/multivariable-model-building.html (2) https://www.nature.com/articles/s41591-018-0134-3. Simulation data are available upon reasonable request to authors. https://www.uniklinik-freiburg.de/imbi/stud-le/multivariable-model-building.html https://www.nature.com/articles/s41591-018-0134-3